| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
Current Controversies in Managing End-Stage Renal Disease Patients |
Department of Medicine, University of Texas Health Sciences Center at San Antonio, San Antonio, Texas
Address correspondence to: Dr. Wajeh Y. Qunibi, Department of Medicine, University of Texas Health Sciences Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900. Phone: 210-422-2692; Fax: 210-358-4710; E-mail: qunibi{at}uthscsa.edu
Patients with chronic kidney disease (CKD) have a higher burden of atherosclerotic coronary artery disease compared with age- and gender-matched individuals with normal renal function. Cardiovascular calcification (CVC), a marker of atherosclerosis, is also more prevalent in these patients and is associated with serious clinical consequences. The pathogenesis of CVC is complex and includes factors that promote calcification and others that inhibit calcification. Thus, multiple therapeutic interventions should be used simultaneously to reduce the burden of calcification in patients with CKD. Thus far, interventional attempts have focused on curtailing the effects of factors that promote calcification such as management of known traditional factors for atherosclerotic coronary artery disease and on adopting specific approaches to normalize mineral metabolism, deliver adequate dialysis, and control serum cholesterol level. By contrast, interventions that may bolster the effects of inhibitors of calcification have not yet been studied well but are beginning to attract attention. Ideally, the goal of interventions is not only to slow or halt progression of calcification but also to reverse pre-existing calcification. Whether this goal is achievable is not currently known. This review examines the potential of various therapeutic interventions in reducing the CVC burden in patients with CKD. Moreover, the review is intended to stimulate more research in this area because the efficacy of these interventions has not been examined in controlled clinical trials.
This article has been cited by other articles:
![]() |
E. Honkanen, L. Kauppila, B. Wikstrom, P. L. Rensma, J.-M. Krzesinski, K. Aasarod, F. Verbeke, P. B. Jensen, P. Mattelaer, B. Volck, et al. Abdominal aortic calcification in dialysis patients: results of the CORD study Nephrol. Dial. Transplant., December 1, 2008; 23(12): 4009 - 4015. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. L. Schiffrin, M. L. Lipman, and J. F.E. Mann Chronic Kidney Disease: Effects on the Cardiovascular System Circulation, July 3, 2007; 116(1): 85 - 97. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. N. Foley Phosphorus Comes of Age as a Cardiovascular Risk Factor Arch Intern Med, May 14, 2007; 167(9): 873 - 874. [Full Text] [PDF] |
||||
![]() |
L. J. Schurgers, H. M. H. Spronk, B. A. M. Soute, P. M. Schiffers, J. G. R. DeMey, and C. Vermeer Regression of warfarin-induced medial elastocalcinosis by high intake of vitamin K in rats Blood, April 1, 2007; 109(7): 2823 - 2831. [Abstract] [Full Text] [PDF] |
||||
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673